06.11.25 -- The 3 Models Of Outsourcing

Join this webinar to explore USP <382>, effective December 1, 2025, covering required testing for elastomeric closures in parenteral drugs. Learn about compliance, instrumentation needs, and testing strategies, with expert guidance from Alcami. Click here to learn more.

Explore the versatility and significance of LFHCs in pharmaceutical and nutraceutical delivery, as well as their role in enhancing drug solubility, bioavailability, and overall efficiency.

Review a case study describing the selection of the optimal solid form of an API designed for pulmonary administration through the pulmonary route.

Whether a biotech is emerging or established, a dedicated CDMO team offers invaluable support through effective communication, technical and regulatory guidance, and adaptability to changing needs.

You want the best shot at a successful CDMO selection, and subsequent relationship – one that thrives during the good times, and survives the stress of development and manufacturing challenges? Your CDMO’s business development (BD) professional is a good place to focus. Here's why.

Through expert insights and real-world case studies, this resource provides valuable perspectives on optimizing HPAPI workflows, ensuring compliance, and leveraging process advancements.

Innovative nasal drug delivery strategies can unlock faster, patient-friendly solutions by combining smart formulation, advanced testing platforms, and rigorous preclinical evaluation.

Learn about the successful commissioning and qualification of Wheeler's Oklahoma City CDMO facility with the overall goal of ensuring all equipment was qualified for a Phase 3 clinical production campaign.

With cutting-edge capabilities and client-focused solutions supporting your drug development journey from concept to commercialization, bringing transformative therapies to patients with speed and quality.

Currently offering support across discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs), with an innovative business model that adds no extra cost to your project.

For poorly soluble drugs, overcoming absorption hurdles can hinder development. Discover a solution that empowers researchers to overcome limitations and accelerate the development of new drugs.

Societal CDMO offers capabilities spanning pre-IND development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms.